Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project

Anny Camelo-Castillo; José Miguel Rivera-Caravaca; Francisco Marín; Vicente Vicente; Gregory Y. H. Lip; Vanessa Roldán

doi:10.1055/s-0040-1712914

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2020; 120(08): 1200-1207
DOI: 10.1055/s-0040-1712914

Stroke, Systemic or Venous Thromboembolism

Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project

Anny Camelo-Castillo ‡^*

¹Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERCV, Murcia, Spain

,

José Miguel Rivera-Caravaca ‡^*

¹Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERCV, Murcia, Spain

,

Francisco Marín

¹Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERCV, Murcia, Spain

,

Vicente Vicente

²Department of Hematology and Clinical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, IMIB-Arrixaca, Murcia, Spain

,

Gregory Y. H. Lip ^**

³Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool, United Kingdom

⁴Department of Clinical Medicine, Aalborg Thrombosis Research Unit, Aalborg University, Aalborg, Denmark

,

Vanessa Roldán ^**

²Department of Hematology and Clinical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, IMIB-Arrixaca, Murcia, Spain

› Institutsangaben

Abstract

Background The ABC (age, biomarkers, and clinical history)-stroke and ABC-bleeding are biomarker-based scores proposed to predict stroke and bleeding, but non-specificity of biomarkers is common, predicting different clinical events at the same time. We assessed the predictive performance of the ABC-stroke and ABC-bleeding scores, for outcomes beyond ischemic stroke and major bleeding, in a cohort of atrial fibrillation (AF) patients.

Methods We included AF patients stable on vitamin K antagonists for 6 months. The ABC-stroke and ABC-bleeding were calculated and the predictive values for myocardial infarction (MI), acute heart failure (HF), a composite of cardiovascular events, and all-cause deaths were compared.

Results We included 1,044 patients (49.2% male; median age 76 [71–81] years). During 6.5 (4.3–7.9) years, there were 58 (5.6%) MIs, 98 (9.4%) acute HFs, 167 (16%) cardiovascular events, and 418 (40%) all-cause deaths. There were no differences in mean ABC-stroke and ABC-bleeding scores in patients with/without MI (p = 0.367 and p = 0.286, respectively); both scores were higher in patients with acute HF, cardiovascular events, or death (all p < 0.05). Predictive performances for the ABC-stroke and ABC-bleeding scores were similar, ranging from “poor” for MI (c-indexes ∼0.54), “moderate” for acute HF and cardiovascular events (c-indexes ∼0.60 and ∼0.64, respectively), and “good” for all-cause mortality (c-indexes > 0.70). Clinical usefulness whether assessed by ABC-stroke or ABC-bleeding was similar for various primary endpoints.

Conclusion In AF patients, the ABC-stroke and ABC-bleeding scores demonstrated similar predictive ability for outcomes beyond stroke and bleeding, including MI, acute HF, a composite of cardiovascular events, and all-cause deaths. This is consistent with nonspecificity of biomarkers that predict “sick” patients or poor prognosis overall.

Keywords

atrial fibrillation - biomarkers - mortality - myocardial infarction - heart failure - ABC-stroke - ABC-bleeding - risk prediction

Volltext

Referenzen

References
1 Andersson T, Magnuson A, Bryngelsson I-L. , et al. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J 2013; 34 (14) 1061-1067
2 January CT, Wann LS, Calkins H. , et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation 2019; 140 (02) e125-e151
3 Kirchhof P, Benussi S, Kotecha D. , et al; ESC Scientific Document Group. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
4 Lip GYH, Banerjee A, Boriani G. , et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest 2018; 154 (05) 1121-1201
5 Violi F, Soliman EZ, Pignatelli P, Pastori D. Atrial fibrillation and myocardial infarction: a systematic review and appraisal of pathophysiologic mechanisms. J Am Heart Assoc 2016; 5 (05) e003347
6 Gorenek Chair B, Halvorsen S, Kudaiberdieva G. , et al. Atrial fibrillation in acute heart failure: a position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. Eur Heart J Acute Cardiovasc Care 2020;
7 Esteve-Pastor MA, Roldán V, Rivera-Caravaca JM, Ramírez-Macías I, Lip GYH, Marín F. The use of biomarkers in clinical management guidelines: a critical appraisal. Thromb Haemost 2019; 119 (12) 1901-1919
8 Borre ED, Goode A, Raitz G. , et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost 2018; 118 (12) 2171-2187
9 Hijazi Z, Lindbäck J, Alexander JH. , et al; ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 2016; 37 (20) 1582-1590
10 Hijazi Z, Oldgren J, Lindbäck J. , et al; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016; 387 (10035): 2302-2311
11 Rivera-Caravaca JM, Esteve-Pastor MA. Heart failure and cardiac events: is a consecutive measurement of biomarkers a simple and practical approach?. Thromb Haemost 2019; 119 (12) 1891-1893
12 Rivera-Caravaca JM, Marín F, Vilchez JA. , et al. Refining stroke and bleeding prediction in atrial fibrillation by adding consecutive biomarkers to clinical risk scores. Stroke 2019; 50 (06) 1372-1379
13 Thygesen K, Alpert JS, Jaffe AS. , et al; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol 2018; 72 (18) 2231-2264
14 Kimenai DM, Henry RMA, van der Kallen CJH. , et al. Direct comparison of clinical decision limits for cardiac troponin T and I. Heart 2016; 102 (08) 610-616
15 Lyngbakken MN, Myhre PL, Røsjø H, Omland T. Novel biomarkers of cardiovascular disease: applications in clinical practice. Crit Rev Clin Lab Sci 2019; 56 (01) 33-60
16 DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44 (03) 837-845
17 Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006; 26 (06) 565-574
18 Lip GY, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 2006; 37 (09) 2294-2300
19 Daubert MA, Jeremias A. The utility of troponin measurement to detect myocardial infarction: review of the current findings. Vasc Health Risk Manag 2010; 6: 691-699
20 Aimo A, Januzzi Jr JL, Vergaro G. , et al. Prognostic value of high-sensitivity troponin T in chronic heart failure: an individual patient data meta-analysis. Circulation 2018; 137 (03) 286-297
21 Agewall S, Giannitsis E, Jernberg T, Katus H. Troponin elevation in coronary vs. non-coronary disease. Eur Heart J 2011; 32 (04) 404-411
22 Kelley WE, Januzzi JL, Christenson RH. Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure. Clin Chem 2009; 55 (12) 2098-2112
23 Lan NSR, Bell DA, McCaul KA. , et al. High-sensitivity cardiac troponin i improves cardiovascular risk prediction in older men: HIMS (The Health in Men Study). J Am Heart Assoc 2019; 8 (05) e011818
24 Maalouf R, Bailey S. A review on B-type natriuretic peptide monitoring: assays and biosensors. Heart Fail Rev 2016; 21 (05) 567-578
25 Courand P-Y, Harbaoui B, Bècle C, Mouly-Bertin C, Lantelme P. Plasma NT-proBNP mirrors the deleterious cardiovascular and renal continuum in hypertension. Eur J Prev Cardiol 2017; 24 (05) 452-459
26 Federico C. Natriuretic peptide system and cardiovascular disease. Heart Views 2010; 11 (01) 10-15
27 Maries L, Manitiu I. Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). Cardiovasc J Afr 2013; 24 (07) 286-289
28 Grote Beverborg N, van Veldhuisen DJ, van der Meer P. Anemia in heart failure: still relevant?. JACC Heart Fail 2018; 6 (03) 201-208
29 Iversen PO, Woldbaek PR, Tønnessen T, Christensen G. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol 2002; 282 (01) R166-R172
30 Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002; 16 (02) 87-96
31 Goddard AF, James MW, McIntyre AS, Scott BB. ; British Society of Gastroenterology. Guidelines for the management of iron deficiency anaemia. Gut 2011; 60 (10) 1309-1316
32 Cases A, Egocheaga MI, Tranche S. , et al. Anemia of chronic kidney disease: protocol of study, management and referral to nephrology. Nefrologia 2018; 38 (01) 8-12
33 Sato Y, Fujimoto S, Konta T. , et al. Anemia as a risk factor for all-cause mortality: obscure synergic effect of chronic kidney disease. Clin Exp Nephrol 2018; 22 (02) 388-394
34 Sankaran VG, Weiss MJ. Anemia: progress in molecular mechanisms and therapies. Nat Med 2015; 21 (03) 221-230
35 Kohne E. Hemoglobinopathies: clinical manifestations, diagnosis, and treatment. Dtsch Arztebl Int 2011; 108 (31-32): 532-540
36 Ajmal A, Gessert CE, Johnson BP, Renier CM, Palcher JA. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels. BMC Res Notes 2013; 6: 443
37 Lee G, Choi S, Kim K, Yun J-M, Son JS, Jeong S-M. , et al. Association between changes in hemoglobin concentration and cardiovascular risks and all-cause mortality among young women. J Am Heart Assoc 2018; 7 (16) e008147-e
38 Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant 2000; 15 (Suppl. 03) 14-18
39 Weiss HJ, Lages B, Hoffmann T, Turitto VT. Correction of the platelet adhesion defect in delta-storage pool deficiency at elevated hematocrit--possible role of adenosine diphosphate. Blood 1996; 87 (10) 4214-4222
40 Anil T. Red blood cells and relation to thrombosis. In: Gemert AWMMK-v, ed. Transfusion Medicine and Scientific Developments. IntechOpen; : July 5th 2017; 2017
41 Udani SM, Koyner JL. The effects of heart failure on renal function. Cardiol Clin 2010; 28 (03) 453-465
42 Warren B, Rebholz CM, Sang Y. , et al. Diabetes and trajectories of estimated glomerular filtration rate: a prospective cohort analysis of the atherosclerosis risk in communities study. Diabetes Care 2018; 41 (08) 1646-1653
43 Berg UB. Long-term followup of renal morphology and function in children with recurrent pyelonephritis. J Urol 1992; 148 (5 Pt 2): 1715-1720
44 Lee JH, Kwon H, Park YW, Cho I-C, Min SK. Relationship of estimated glomerular filtration rate with lower urinary tract symptoms/benign prostatic hyperplasia measures in middle-aged men with moderate to severe lower urinary tract symptoms. Urology 2013; 82 (06) 1381-1385
45 Gillen DL, Worcester EM, Coe FL. Decreased renal function among adults with a history of nephrolithiasis: a study of NHANES III. Kidney Int 2005; 67 (02) 685-690
46 Yap E, Salifu M, Ahmad T, Sanusi A, Joseph A, Mallappallil M. Atypical causes of urinary tract obstruction. Case Rep Nephrol 2019; 2019: 4903693
47 Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA. , et al. Long-term stroke risk prediction in patients with atrial fibrillation: comparison of the ABC-stroke and CHA₂DS₂-VASc scores. J Am Heart Assoc 2017; 6 (07) e006490
48 Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V. , et al. Long-term bleeding risk prediction in ‘real world’ patients with atrial fibrillation: comparison of the HAS-BLED and ABC-bleeding risk scores. The Murcia Atrial Fibrillation Project. Thromb Haemost 2017; 117 (10) 1848-1858
49 Proietti M, Mujovic N, Potpara TS. Optimizing stroke and bleeding risk assessment in patients with atrial fibrillation: a balance of evidence, practicality and precision. Thromb Haemost 2018; 118 (12) 2014-2017
50 Ban N, Siegfried CJ, Apte RS. Monitoring neurodegeneration in glaucoma: therapeutic implications. Trends Mol Med 2018; 24 (01) 7-17
51 Hijazi Z, Wallentin L, Siegbahn A. , et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol 2013; 61 (22) 2274-2284
52 Hijazi Z, Oldgren J, Andersson U. , et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation 2012; 125 (13) 1605-1616
53 Ruff CT, Giugliano RP, Braunwald E. , et al. Cardiovascular biomarker score and clinical outcomes in patients with atrial fibrillation: a subanalysis of the ENGAGE AF-TIMI 48 randomized clinical trial. JAMA Cardiol 2016; 1 (09) 999-1006